Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
IPO Year: 1996
Exchange: NASDAQ
Website: neurocrine.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/11/2025 | $138.00 | Hold | Deutsche Bank |
10/10/2024 | $155.00 | Outperform | Raymond James |
8/29/2024 | $131.00 → $159.00 | Neutral → Overweight | Piper Sandler |
4/24/2024 | $140.00 → $170.00 | Equal Weight → Overweight | Wells Fargo |
12/13/2023 | $127.00 | Neutral | Citigroup |
12/12/2023 | $136.00 | Buy | Deutsche Bank |
10/24/2023 | $135.00 → $140.00 | Overweight | Cantor Fitzgerald |
8/21/2023 | $112.00 → $113.00 | Neutral | Mizuho |
7/24/2023 | $115.00 → $125.00 | Market Perform → Outperform | SVB Securities |
7/6/2023 | $91.00 → $96.00 | Underperform → Market Perform | BMO Capital Markets |
All Patients Treated with INGREZZA® (valbenazine) Capsules Reached a Therapeutic Dose from Day One, While Only Approximately Half of Patients Treated with Deutetrabenazine Were Able to Reach a Therapeutic Dose Within Six MonthsFindings Presented at the Academy of Managed Care Pharmacy 2025 Annual MeetingSAN DIEGO, March 31, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the presentation of new data from a real-world study showing that all patients with tardive dyskinesia achieved a therapeutic dose with INGREZZA® (valbenazine) capsules upon initiation of treatment. This retrospective cohort study will be presented at the Academy of Managed Care Pharmacy 2025
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric DisorderFindings Presented at the 2025 Psychiatry Update ConferenceSAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago. "These findings f
Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease ChoreaFindings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced Practice Provider SymposiumSAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA® (valbenazine) capsules in adults with Huntington's disease. The post-hoc analysis was presented at the Neuroscience Advanced Practice Provider Symposium hosted by the American Association of Neuroscience Nurses in New Orleans.
SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer Eiry Roberts will present at the conference. The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month. About Neurocr
SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an investigational, oral, selective second-generation small molecule inhibitor of the vesicular monoamine transporter 2 (VMAT2) in development for the potential treatment of certain neurological and neuropsychiatric conditions. "We are focused on extending our bench of VMAT2
SAN DIEGO, Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of INGREZZA® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (TD), irrespective of TD severity or underlying psychiatric condition. KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale used to evaluate the physical, social and emotional im
SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston.Chief Financial Officer Matt Abernethy and Vice-President of Investor Relations Todd Tushla will present at the Leerink Global Healthcare Conference on Tuesday, March 11, 2025 at 11:20 AM East
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025. William Rastetter, Chairman of the Board of Directors of Neurocrine Biosciences, said, "This authorization reflects
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO, Feb. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quart
Conference Call and Webcast Scheduled for Thursday, February 6 SAN DIEGO, Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 6, 2025. The schedule for the press release and conference call / webcast is as follows: Q4 & Year-End 2024 Press Release: February 6, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ4 & Year-End 2024 Conference Call: February 6, 2025 at 1:30 p.m. PT / 4:30 p.m. E
For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con
SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SCHEDULE 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
144 - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
144 - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
10-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
SCHEDULE 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
10-Q - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO, Feb. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quart
Conference Call and Webcast Scheduled for Thursday, February 6 SAN DIEGO, Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 6, 2025. The schedule for the press release and conference call / webcast is as follows: Q4 & Year-End 2024 Press Release: February 6, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ4 & Year-End 2024 Conference Call: February 6, 2025 at 1:30 p.m. PT / 4:30 p.m. E
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO, Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an update on its 2024 financial guidance. "With continued INGREZZA growth across the tardive dyskinesia and Huntington's disease chorea indications,
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on October 30, 2024. The schedule for the press release and conference call / webcast is as follows: • Q3 2024 Press Release: October 30, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q3 2024 Conference Call: October 30, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic D
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe once-daily 20 mg dose efficacy, safety and tolerability Phase 2 results support advancement to Phase 3 in schizophrenia in early 2025The once-daily 20 mg dose met the primary endpoint, demonstrating a statistically significant 7.5-point improvement (p=0.011, 0.61 effect size) in the PANSS total score compared to placebo at week 6 with an 18.2-point PANSS total score improvement from baselineThe once-daily 20 mg dose met additional endpoints, demonstrating statistically significant improvements in Clinica
The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from BaselineThe Once-Daily 20 mg Dose Met Additional Endpoints, Demonstrating Statistically Significant Improvements in Clinical Global Impression of Severity Scale and Marder Factor Score Positive Symptom Change and Negative Symptom ChangeNBI-'568 Was Generally Safe and Well Tolerated at All Doses StudiedThe Once-Daily 20 mg Dose Efficacy, Safety and Tolerability Phase 2 Results Support Advancement to Phase 3 in Schizophrenia in Early 2025Company
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO, Aug. 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2024 and provided an update on its 2024 financial guidance. "At Neurocrine, we are energized by the tremendous opportunity we see to help many
Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO, July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on August 1, 2024. The schedule for the press release and conference call / webcast is as follows: • Q2 2024 Press Release: August 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q2 2024 Conference Call: August 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic Dial-In Numb
INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA Positive Phase 2 Top-Line Data for NBI-1065845, a Potential First-In-Class AMPA Positive Allosteric Modulator, in Adults with Major Depressive Disorder SAN DIEGO, May 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance.
Conference Call and Webcast Scheduled for Wednesday, May 1 SAN DIEGO, April 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 1, 2024. The schedule for the press release and conference call / webcast is as follows: • Q1 2024 Press Release: May 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q1 2024 Conference Call: May 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic Dial-In Number: 800-343-4136
Deutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Hold and set a new price target of $138.00
Raymond James resumed coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $155.00
Piper Sandler upgraded Neurocrine Biosciences from Neutral to Overweight and set a new price target of $159.00 from $131.00 previously
Wells Fargo upgraded Neurocrine Biosciences from Equal Weight to Overweight and set a new price target of $170.00 from $140.00 previously
Citigroup resumed coverage of Neurocrine Biosciences with a rating of Neutral and set a new price target of $127.00
Deutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $136.00
Cantor Fitzgerald resumed coverage of Neurocrine Biosciences with a rating of Overweight and set a new price target of $140.00 from $135.00 previously
Mizuho reiterated coverage of Neurocrine Biosciences with a rating of Neutral and set a new price target of $113.00 from $112.00 previously
SVB Securities upgraded Neurocrine Biosciences from Market Perform to Outperform and set a new price target of $125.00 from $115.00 previously
BMO Capital Markets upgraded Neurocrine Biosciences from Underperform to Market Perform and set a new price target of $96.00 from $91.00 previously
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neurocrine Board of Directors SAN DIEGO, May 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role. Dr. Gano will also join the Company's Board of Directors at that time, and Dr. Gorman will continue to serve on the Neurocrine Board.
SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors. "Christine Poon brings a wealth of industry experience to Neurocrine's Board of Directors," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Her strong track record in leadership positions at some of the most established global biopharmaceutical enterprises will serve Neurocrine well." Ms. Poon has demonstrated br
SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021. "Ingrid's deep experience in regulatory affairs will be invaluable to Neurocrine as we work to advance our pipeline in our quest to relieve suffering for people with
SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Jude Onyia, Ph.D., has joined the company's executive management team as Chief Scientific Officer. Dr. Onyia, a scientist with more than 25 years of experience in the pharmaceutical industry, will lead the drug discovery and non-clinical development teams responsible for bolstering and advancing the company's pipeline of therapeutic candidates. Dr. Onyia most recently was the Chief Scientific Officer at Capsida Biotherapeutics. Prior to that, he spent 25 years at Eli Lilly
SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's medicines. "We are pleased to add Johanna Mercier to the Board of Directors at Neurocrine Biosciences," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Johanna is an accomplished commercial leader and her extensive global experience within the biopharmaceutical